| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| Acetaminophen (103-90-2) | Hepatic Failure | Antagonistic | Not Clear | Paracetamol as a test drug to determine glucuronide formation in man Effects of inducers and of smoking
|
| Tamoxifen (10540-29-1) | Efficacy Of Tamoxifen Reduced | Antagonistic | Rifampicin induces the metabolism of tamoxifen by the cytochrome P450 isoenzyme CYP3A4, thereby reducing its levels | Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin
|
| Bunazosin (80755-51-7) | Reduced Bunazosin Serum Levels | Antagonistic | Rifampicin increases the metabolism of bunazosin by the liver | 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
|
| Clarithromycin (81103-11-9) | Neutropenia | Additive | Rifampicin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels. Rifampicin is recognised as being the more potent inducer | Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
|
| Clarithromycin (81103-11-9) | Uveitis | Additive | Rifampicin is enzyme inducers, which can increase the metabolism of other drugs by the liver, thereby reducing their serum levels. Rifampicin is recognised as being the more potent inducer | Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
|
| Fluconazole (86386-73-4) | Hypercalcaemia | Antagonistic | Rifampicin increases the metabolism of the azole antifungals by the liver | Induction of fluconazole metabolism by rifampin: in vivo study in humans
|
| Imatinib (152459-95-5) | Lower Serum Imatinib Levels | Antagonistic | Rifampicin is a known potent inducer of many cytochrome P450 isoenzymes, including CYP3A4, by which imatinib is metabolised | Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
|
| Ifosfamide (3778-73-2) | Decreased Efficacy | Antagonistic | Rifampicin is an inducer of the cytochrome P450 isoenzymes CYP3A4 and CYP2B6, which are involved in the metabolism of ifosfamide | Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin
|
| Isoniazid (54-85-3) | Hepatotoxicity | Additive | Not understood | Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid
|
| Enalapril (75847-73-3) | Rise In Blood Pressure | Antagonistic | Not Clear | A possible drug interaction between rifampicin and enalapril
|
| Dapsone (80-08-0) | Methaemoglobinaemia | Antagonistic | Rifampicin increase the metabolism and clearance of dapsone. Rifampicin also increases the blood levels of the toxic hydroxylamine metabolite of dapsone | Drug interaction during multidrug regimens for treatment of leprosy
|
| Lamotrigine (84057-84-1) | Decreased Auc Of Lamotrigine | Antagonistic | Rifampicin increases the loss of lamotrigine from the body, probably by inducing glucuronidation via UDP-glucuronyl transferases | Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects
|